XML 168 R85.htm IDEA: XBRL DOCUMENT
v3.20.4

Segmentation of key figures - Top 20 (Details 9) - USD ($) $ in Millions | 12 Months Ended
--- | ---
Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | $ 48,659 | $ 47,445 | $ 44,751
US |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | 16,484 | 16,280 | 14,618
Innovative Medicines | Top 20 products [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | 29,916 | 28,646 | 26,946
Innovative Medicines | Rest of portfolio [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | 9,097 | 9,068 | 7,946
Innovative Medicines | Oncology [member] | Top 20 products [member] | Tasigna [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | 1,958 | 1,880 | 1,587
Innovative Medicines | Oncology [member] | Top 20 products [member] | Sandostatin [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | 1,439 | 1,726 | 1,561
Innovative Medicines | Oncology [member] | Top 20 products [member] | Afinitor/Votubia [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | 1,083 | 1,539 | 1,556
Innovative Medicines | Oncology [member] | Top 20 products [member] | Promacta/Revolade [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | 1,738 | 1,338 | 1,023
Innovative Medicines | Oncology [member] | Top 20 products [member] | Tafinlar + Mekinist [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | 1,542 | 1,297 | 1,028
Innovative Medicines | Oncology [member] | Top 20 products [member] | Gleevec/Glivec [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | 1,188 | 1,585 | 2,046
Innovative Medicines | Oncology [member] | Top 20 products [member] | Jakavi [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | 1,339 | 975 | 977
Innovative Medicines | Oncology [member] | Top 20 products [member] | Exjade/Jadenu [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | 653 | 1,263 | 1,174
Innovative Medicines | Oncology [member] | Top 20 products [member] | Votrient [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | 635 | 755 | 1,002
Innovative Medicines | Pharmaceutical [member] | Top 20 products [member] | Lucentis [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | 1,933 |  |
Innovative Medicines | Pharmaceutical [member] | Ophthalmology [member] | Top 20 products [member] | Lucentis [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations |  | 2,086 | 1,874
Innovative Medicines | Pharmaceutical [member] | Ophthalmology [member] | Top 20 products [member] | Travoprost Group [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations |  | 485 | 828
Innovative Medicines | Pharmaceutical [member] | Neuroscience [member] | Top 20 products [member] | Gilenya [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | 3,003 | 3,551 | 3,341
Innovative Medicines | Pharmaceutical [member] | Neuroscience [member] | Top 20 products [member] | Zolgensma [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | 920 |  |
Innovative Medicines | Pharmaceutical [member] | Respiratory [member] | Top 20 products [member] | Xolair [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | 1,251 | 1,173 | 1,039
Innovative Medicines | Pharmaceutical [member] | Cardiovascular, Renal and Metabolism [member] | Top 20 products [member] | Entresto [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | 2,497 | 1,114 | 554
Innovative Medicines | Pharmaceutical [member] | Established Medicines [member] | Top 20 products [member] | Galvus Group [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | 1,199 | 1,416 | 1,284
Innovative Medicines | Pharmaceutical [member] | Established Medicines [member] | Top 20 products [member] | Diovan Group [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | 1,003 | 1,064 | 1,099
Innovative Medicines | Pharmaceutical [member] | Established Medicines [member] | Top 20 products [member] | Exforge Group [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | 980 | 1,025 | 1,155
Innovative Medicines | Pharmaceutical [member] | Established Medicines [member] | Top 20 products [member] | Zortress/Certican [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations |  | 480 |
Innovative Medicines | Pharmaceutical [member] | Established Medicines [member] | Top 20 products [member] | Kisqali [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | 687 |  |
Innovative Medicines | Pharmaceutical [member] | Established Medicines [member] | Top 20 products [member] | Voltaren/Cataflam [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations |  |  | 464
Innovative Medicines | Pharmaceutical [member] | Immunology, Hepatology and Dermatology [member] | Top 20 products [member] | Cosentyx [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | 3,995 | 3,223 | 2,837
Innovative Medicines | Pharmaceutical [member] | Immunology, Hepatology and Dermatology [member] | Top 20 products [member] | Ilaris [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | 873 | 671 |
Innovative Medicines | Pharmaceutical [member] | Immunology, Hepatology and Dermatology [member] | Top 20 products [member] | Neoral/Sandimmun(e) [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations |  |  | 517
Innovative Medicines | US |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | 14,342 | 13,789 | 11,864
Innovative Medicines | US | Top 20 products [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | 11,126 | 10,679 | 9,654
Innovative Medicines | US | Rest of portfolio [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | 3,216 | 3,110 | 2,210
Innovative Medicines | US | Oncology [member] | Top 20 products [member] | Tasigna [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | 859 | 804 | 817
Innovative Medicines | US | Oncology [member] | Top 20 products [member] | Sandostatin [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | 837 | 925 | 440
Innovative Medicines | US | Oncology [member] | Top 20 products [member] | Afinitor/Votubia [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | 644 | 1,003 | 929
Innovative Medicines | US | Oncology [member] | Top 20 products [member] | Promacta/Revolade [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | 833 | 481 | 84
Innovative Medicines | US | Oncology [member] | Top 20 products [member] | Tafinlar + Mekinist [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | 569 |  | 556
Innovative Medicines | US | Oncology [member] | Top 20 products [member] | Gleevec/Glivec [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | 315 | 881 |
Innovative Medicines | US | Oncology [member] | Top 20 products [member] | Jakavi [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations |  | 450 |
Innovative Medicines | US | Oncology [member] | Top 20 products [member] | Exjade/Jadenu [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | 138 | 334 | 581
Innovative Medicines | US | Oncology [member] | Top 20 products [member] | Votrient [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | 259 | 332 | 19
Innovative Medicines | US | Pharmaceutical [member] | Ophthalmology [member] | Top 20 products [member] | Lucentis [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations |  |  | 806
Innovative Medicines | US | Pharmaceutical [member] | Ophthalmology [member] | Top 20 products [member] | Travoprost Group [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations |  | 169 | 404
Innovative Medicines | US | Pharmaceutical [member] | Neuroscience [member] | Top 20 products [member] | Gilenya [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | 1,562 | 2,220 | 1,765
Innovative Medicines | US | Pharmaceutical [member] | Neuroscience [member] | Top 20 products [member] | Zolgensma [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | 459 |  |
Innovative Medicines | US | Pharmaceutical [member] | Cardiovascular, Renal and Metabolism [member] | Top 20 products [member] | Entresto [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | 1,277 |  | 262
Innovative Medicines | US | Pharmaceutical [member] | Established Medicines [member] | Top 20 products [member] | Galvus Group [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations |  | 691 |
Innovative Medicines | US | Pharmaceutical [member] | Established Medicines [member] | Top 20 products [member] | Diovan Group [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | 124 | 86 | 521
Innovative Medicines | US | Pharmaceutical [member] | Established Medicines [member] | Top 20 products [member] | Exforge Group [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | 16 | 13 | 457
Innovative Medicines | US | Pharmaceutical [member] | Established Medicines [member] | Top 20 products [member] | Zortress/Certican [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations |  | 250 |
Innovative Medicines | US | Pharmaceutical [member] | Established Medicines [member] | Top 20 products [member] | Kisqali [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | 318 |  |
Innovative Medicines | US | Pharmaceutical [member] | Established Medicines [member] | Top 20 products [member] | Voltaren/Cataflam [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations |  |  | 145
Innovative Medicines | US | Pharmaceutical [member] | Immunology, Hepatology and Dermatology [member] | Top 20 products [member] | Cosentyx [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | 2,516 | 1,736 | 1,674
Innovative Medicines | US | Pharmaceutical [member] | Immunology, Hepatology and Dermatology [member] | Top 20 products [member] | Ilaris [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | 400 | 304 |
Innovative Medicines | US | Pharmaceutical [member] | Immunology, Hepatology and Dermatology [member] | Top 20 products [member] | Neoral/Sandimmun(e) [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations |  |  | 194
Innovative Medicines | Rest of the world [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | 24,671 | 23,925 | 23,028
Innovative Medicines | Rest of the world [member] | Top 20 products [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | 18,790 | 17,967 | 17,292
Innovative Medicines | Rest of the world [member] | Rest of portfolio [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | 5,881 | 5,958 | 5,736
Innovative Medicines | Rest of the world [member] | Oncology [member] | Top 20 products [member] | Tasigna [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | 1,099 | 1,076 | 770
Innovative Medicines | Rest of the world [member] | Oncology [member] | Top 20 products [member] | Sandostatin [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | 602 | 801 | 1,121
Innovative Medicines | Rest of the world [member] | Oncology [member] | Top 20 products [member] | Afinitor/Votubia [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | 439 | 536 | 627
Innovative Medicines | Rest of the world [member] | Oncology [member] | Top 20 products [member] | Promacta/Revolade [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | 905 | 857 | 939
Innovative Medicines | Rest of the world [member] | Oncology [member] | Top 20 products [member] | Tafinlar + Mekinist [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | 973 | 1,297 | 472
Innovative Medicines | Rest of the world [member] | Oncology [member] | Top 20 products [member] | Gleevec/Glivec [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | 873 | 704 | 2,046
Innovative Medicines | Rest of the world [member] | Oncology [member] | Top 20 products [member] | Jakavi [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | 1,339 | 525 | 977
Innovative Medicines | Rest of the world [member] | Oncology [member] | Top 20 products [member] | Exjade/Jadenu [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | 515 | 929 | 593
Innovative Medicines | Rest of the world [member] | Oncology [member] | Top 20 products [member] | Votrient [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | 376 | 423 | 983
Innovative Medicines | Rest of the world [member] | Pharmaceutical [member] | Top 20 products [member] | Lucentis [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | 1,933 |  |
Innovative Medicines | Rest of the world [member] | Pharmaceutical [member] | Ophthalmology [member] | Top 20 products [member] | Lucentis [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations |  | 2,086 | 1,068
Innovative Medicines | Rest of the world [member] | Pharmaceutical [member] | Ophthalmology [member] | Top 20 products [member] | Travoprost Group [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations |  | 316 | 424
Innovative Medicines | Rest of the world [member] | Pharmaceutical [member] | Neuroscience [member] | Top 20 products [member] | Gilenya [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | 1,441 | 1,331 | 1,576
Innovative Medicines | Rest of the world [member] | Pharmaceutical [member] | Neuroscience [member] | Top 20 products [member] | Zolgensma [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | 461 |  |
Innovative Medicines | Rest of the world [member] | Pharmaceutical [member] | Respiratory [member] | Top 20 products [member] | Xolair [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | 1,251 | 1,173 | 1,039
Innovative Medicines | Rest of the world [member] | Pharmaceutical [member] | Cardiovascular, Renal and Metabolism [member] | Top 20 products [member] | Entresto [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | 1,220 | 1,114 | 292
Innovative Medicines | Rest of the world [member] | Pharmaceutical [member] | Established Medicines [member] | Top 20 products [member] | Galvus Group [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | 1,199 | 725 | 1,284
Innovative Medicines | Rest of the world [member] | Pharmaceutical [member] | Established Medicines [member] | Top 20 products [member] | Diovan Group [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | 879 | 978 | 578
Innovative Medicines | Rest of the world [member] | Pharmaceutical [member] | Established Medicines [member] | Top 20 products [member] | Exforge Group [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | 964 | 1,012 | 698
Innovative Medicines | Rest of the world [member] | Pharmaceutical [member] | Established Medicines [member] | Top 20 products [member] | Zortress/Certican [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations |  | 230 |
Innovative Medicines | Rest of the world [member] | Pharmaceutical [member] | Established Medicines [member] | Top 20 products [member] | Kisqali [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | 369 |  |
Innovative Medicines | Rest of the world [member] | Pharmaceutical [member] | Established Medicines [member] | Top 20 products [member] | Voltaren/Cataflam [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations |  |  | 319
Innovative Medicines | Rest of the world [member] | Pharmaceutical [member] | Immunology, Hepatology and Dermatology [member] | Top 20 products [member] | Cosentyx [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | 1,479 | 1,487 | 1,163
Innovative Medicines | Rest of the world [member] | Pharmaceutical [member] | Immunology, Hepatology and Dermatology [member] | Top 20 products [member] | Ilaris [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | 473 | 367 |
Innovative Medicines | Rest of the world [member] | Pharmaceutical [member] | Immunology, Hepatology and Dermatology [member] | Top 20 products [member] | Neoral/Sandimmun(e) [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations |  |  | 323
Operating segments [member] | Innovative Medicines |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | 39,013 | 37,714 | 34,892
Operating segments [member] | Innovative Medicines | Oncology [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | 14,711 | 14,370 | 13,428
Operating segments [member] | Innovative Medicines | Oncology [member] | Tasigna [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | 1,958 | 1,880 | 1,874
Operating segments [member] | Innovative Medicines | Oncology [member] | Sandostatin [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | 1,439 | 1,585 | 1,587
Operating segments [member] | Innovative Medicines | Oncology [member] | Afinitor/Votubia [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | 1,083 | 1,539 | 1,556
Operating segments [member] | Innovative Medicines | Oncology [member] | Promacta/Revolade [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | 1,738 | 1,416 | 1,174
Operating segments [member] | Innovative Medicines | Oncology [member] | Tafinlar + Mekinist [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | 1,542 | 1,338 | 1,155
Operating segments [member] | Innovative Medicines | Oncology [member] | Gleevec/Glivec [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | 1,188 | 1,263 | 1,561
Operating segments [member] | Innovative Medicines | Oncology [member] | Jakavi [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | 1,339 | 1,114 | 977
Operating segments [member] | Innovative Medicines | Oncology [member] | Exjade/Jadenu [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | 653 | 975 | 1,099
Operating segments [member] | Innovative Medicines | Oncology [member] | Votrient [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | 635 | 755 | 828
Operating segments [member] | Innovative Medicines | Oncology [member] | Kisqali [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | 687 | 480 | 235
Operating segments [member] | Innovative Medicines | Oncology [member] | Adakveo [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | 105 | 1 |
Operating segments [member] | Innovative Medicines | Pharmaceutical [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | 24,302 | 23,344 | 21,464
Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Ophthalmology [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | 4,410 | 4,776 | 4,558
Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Ophthalmology [member] | Lucentis [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | 1,933 | 2,086 | 2,046
Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Neuroscience [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | 4,323 | 3,773 | 3,429
Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Neuroscience [member] | Gilenya [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | 3,003 | 3,223 | 3,341
Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Neuroscience [member] | Zolgensma [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | 920 | 361 |
Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Neuroscience [member] | Kesimpta [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | 15 |  |
Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Respiratory [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | 1,900 | 1,825 | 1,767
Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Respiratory [member] | Xolair [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | 1,251 | 1,173 | 1,039
Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Cardiovascular, Renal and Metabolism [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | 2,498 | 1,750 | 1,050
Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Cardiovascular, Renal and Metabolism [member] | Entresto [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | 2,497 | 1,726 | 1,028
Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Established Medicines [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | 6,303 | 6,998 | 7,268
Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Established Medicines [member] | Galvus Group [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | 1,199 | 1,297 | 1,284
Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Established Medicines [member] | Diovan Group [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | 1,003 | 1,064 | 1,023
Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Established Medicines [member] | Exforge Group [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | 980 | 1,025 | 1,002
Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Established Medicines [member] | Zortress/Certican [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | 452 | 485 | 464
Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Established Medicines [member] | Neoral/Sandimmun(e) [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | 393 | 419 | 463
Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Established Medicines [member] | Voltaren/Cataflam [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | 360 | 417 | 445
Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Immunology, Hepatology and Dermatology [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | 4,868 | 4,222 | 3,392
Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Immunology, Hepatology and Dermatology [member] | Cosentyx [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | 3,995 | 3,551 | 2,837
Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Immunology, Hepatology and Dermatology [member] | Ilaris [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties from continuing operations | $ 873 | $ 671 | $ 554

X
- Definition Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table. + References No definition available. + Details
Name: | ifrs-full_DisclosureOfOperatingSegmentsLineItems
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | nvs_RevenueFromSaleOfGoodsThirdParties
Namespace Prefix: | nvs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | ifrs-full_GeographicalAreasAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | nvs_ProductPortfolioAxis=nvs_Top20ProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | nvs_ProductPortfolioAxis=nvs_RestOfPortfolioMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | nvs_BusinessUnitAxis=nvs_OncologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_TasignaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_SandostatinMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_AfinitorVotubiaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_PromactaRevoladeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_TafinlarMekinistMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_GleevecGlivecMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_JakaviMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_ExjadeJadenuMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_VotrientMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | nvs_BusinessUnitAxis=nvs_PharmaceuticalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_LucentisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | nvs_FranchiseAxis=nvs_OphthalmologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_TravoprostGroupMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | nvs_FranchiseAxis=nvs_NeuroscienceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_GilenyaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_ZolgensmaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | nvs_FranchiseAxis=nvs_RespiratoryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_XolairMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | nvs_FranchiseAxis=nvs_CardioMetabolicMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_EntrestoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | nvs_FranchiseAxis=nvs_EstablishedMedicinesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_GalvusGroupMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_DiovanGroupMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_ExforgeGroupMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_ZortressCerticanMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_KisqaliMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_VoltarenCataflamMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | nvs_FranchiseAxis=nvs_ImmunologyHepatologyAndDermatologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_CosentyxMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_IlarisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_NeoralSandimmunEMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_GeographicalAreasAxis=nvs_RestOfTheWorldMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_AdakveoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_KesimptaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |